Market Overview - The Hong Kong stock market opened higher with the Hang Seng Index rising by 0.23% to 27,246.18 points, the Hang Seng Tech Index up by 0.21% to 5,462.7 points, and the National Enterprises Index increasing by 0.17% to 9,258.27 points, indicating a mixed trading environment near key technical levels [1] Blue Chip Performance - Semiconductor company SMIC reported a significant increase in capacity utilization, reaching 93.5% in 2025, an 8 percentage point increase year-on-year, with projected sales revenue of $9.327 billion, a 16.2% increase, and net profit of $685 million, up 39.1% [2] - PCCW expects a revenue growth of 7% to HKD 40.252 billion in 2025, with EBITDA increasing by 3% and losses narrowing by 16% [2] - Television Broadcasts Limited anticipates turning a profit, while Dongyue Group expects profit growth of over 100% [2] Consumer and Real Estate Sector Challenges - Bosideng International reported a 32.5% year-on-year decline in net operating income for January, while Yue Yuen Industrial saw a 12.5% decrease [3] - The real estate sector is under pressure, with New World Development announcing a 29.79% year-on-year drop in contract sales for January, and Yuzhou Group reporting a slight increase of 5.79%, but market skepticism about overall industry recovery persists [3] Company Developments - Minth Group announced a joint venture with Aisin and Toyota to produce aluminum vehicle body components, aiming to strengthen its supply chain in the North American market [4] - Stone Four Pharmaceutical Group plans to participate in the eighth batch of national centralized procurement with 45 products across various treatment areas [5] - Gilead Sciences completed a placement raising approximately HKD 835 million, with 90% allocated for global Phase III clinical trials of an oral GLP-1 receptor agonist for obesity [5] Institutional Insights - Industrial Securities noted that the ongoing loose overseas liquidity environment and expectations of interest rate cuts by the Federal Reserve could lead to foreign capital inflows into Hong Kong stocks in 2026 [6] - The recent stabilization in Hong Kong stocks, particularly in the Hang Seng Tech sector, suggests potential for valuation recovery and performance realization in AI, innovative pharmaceuticals, and high-dividend sectors [6] - Guotai Junan Securities highlighted the potential for a phase of upward movement in Hong Kong stocks around the Lunar New Year, with increased correlation to A-shares [6] Focus on Innovative Pharmaceuticals - Open Source Securities expressed optimism about the innovative pharmaceutical sector, noting that the total value of License-out transactions has exceeded last year's figures, and the quality of China's innovative drug pipeline is improving [7]

Group 1: CRO Industry Insights - Since 2025, domestic CRO orders have shown a trend of simultaneous volume and price increase, benefiting from the overseas expansion of innovative drugs and stable financing recovery [1] - Multiple CROs have accelerated new order signing quarterly, achieving double-digit growth in project volume, with a price increase trend observed in experimental monkeys, safety evaluation quotes, and clinical project pricing since Q4 [1] - The performance of CROs is expected to enter an improvement cycle by 2026, driven by strong customer demand and the continuous strengthening of China's global competitiveness in innovative drugs [1] Group 2: Innovative Drug Market Dynamics - Despite previous adjustments in the innovative drug sector, the logic of strengthening global competitiveness, successful overseas expansion, and realization of commercial profits remains unchanged [1] - In the past two years, China has experienced a "big year" for innovative drug overseas expansion, with record highs in both the number and value of licensing-out transactions [1] - In 2025, the number of new drug license-out transactions in China is expected to reach 158, with a total transaction scale of $135.7 billion and an upfront payment scale of $7 billion, marking a ten-year high in both transaction quantity and value [1] Group 3: Brain-Computer Interface (BCI) Developments - The BCI sector is advancing with multiple technological routes underpinned by AI integration and supportive policies, accelerating the commercialization growth cycle [2] - BCIs serve as a direct information exchange channel between the biological brain and external devices, enabling brain function replacement, repair, enhancement, and optimization [2] - In the global landscape, the US leads in invasive technologies while China has made breakthroughs in non-invasive and language decoding fields, with both countries showing minimal technological lag [2] Group 4: Policy and Capital Support for BCI - The BCI industry is included in the "14th Five-Year Plan," with various policies supporting technological innovation, application scenarios, and medical insurance payments, facilitating industry standardization and clinical transformation [2] - Capital investment in the BCI sector has significantly increased, with a multiple growth in financing events and amounts expected by 2025, indicating a strong recovery in investor interest [2] - Although the financing structure shows early-stage characteristics, leading companies have received substantial capital injections, leading to a gradual emergence of industrial clustering effects [2]

近期，随着创新药企业陆续披露2025年报及业绩预告，多家企业展现出良好的经营改善态势，在报告期 内实现亏损收窄甚至业绩转正，释放出积极信号。在此背景下，创新药及相关板块再引关注。公告显 示，工银瑞信中证港股通医疗主题交易型开放式指数证券投资基金（简称：港股通医疗ETF工银；代 码：159167）将于2026年2月12日起在深交所上市交易。 公开资料显示，港股通医疗ETF工银（159167）紧密跟踪中证港股通医疗主题指数（代码： 932069.CSI），该指数锚定医疗创新，全面覆盖港股"CXO +互联网医疗+医疗器械+创新药"等医药各领 域核心龙头，并囊括脑机接口、AI医疗、高端医疗器械等热门主题；该指数弹性足，估值具有吸引 力。Wind数据显示，截至2026年2月10日，中证港股通医疗主题指数目前市盈率（TTM）为32.85倍， 处于发布以来48.16%分位，指数当前或未被高估，或仍具有吸引力。 国金证券指出，2025年中国新药License-out交易数量达158笔、总规模1357亿美元，创近十年新高；出 海BD繁荣不仅显著提振短期业绩预期，更推动国产新药国际化开发进程与远期价值提升。申万宏源研 究研报观点 ...

Group 1 - Seedance2.0 is expected to be a pivotal moment for AI in the film industry, particularly in the production of AI comics and short dramas, leading to significant cost reductions and efficiency improvements in content creation [2] - The release of Seedance2.0 has sparked widespread evaluation and discussion within the industry, showcasing impressive capabilities in multi-modal thinking and video generation from various input types [2] - The film and television sector saw a substantial increase, with the film industry index rising by 13.83%, significantly outperforming other sectors, driven by the excitement around AI applications [2] Group 2 - The innovative pharmaceutical sector is experiencing a resurgence, with notable stock price increases among companies such as Wanbangde and Guangshengtang, indicating renewed investor interest [3] - The National Medical Products Administration announced that by 2025, China's pharmaceutical industry will accelerate its internationalization, with cumulative overseas licensing transactions for innovative drugs expected to exceed $130 billion [3] - A strategic cooperation agreement between Shiyao Group and AstraZeneca could yield up to $18.5 billion, marking a significant milestone in the company's business development transactions [3] Group 3 - Emerging technologies remain a key focus for the market, with a recommendation to concentrate on sectors benefiting from AI applications and international expansion [4] - The recent volatility in the Chinese stock market is attributed to global financial tightening concerns and pre-holiday cautious sentiment, but there is optimism regarding the domestic economic outlook [4] - The semiconductor sales growth is projected to accelerate, with high demand for domestic chips and related industries expected to continue through 2026 [4][5]

Group 1 - The JPM 2026 conference revealed innovative opportunities in the pharmaceutical and medical device sectors, particularly in the IO plus field where the trend of using VEGF dual antibodies in multiple indications is becoming established [1] - There is a focus on multinational corporations (MNCs) and leading biotech companies developing dual antibodies and combinations with monoclonal antibodies targeting other immune-related sites [1] - In the ADC (Antibody-Drug Conjugate) area, attention is drawn to first-in-class (FIC) products for large indications, new indications for major products, and advancements in dual toxin/new toxin ADC technologies, which are leading directions for domestic innovative drugs [1] Group 2 - The ETF Guotai (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20%, and selects listed companies engaged in biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine, and medical services [2] - The index emphasizes the R&D investment and technological leadership of constituent companies, focusing on high-growth potential in the pharmaceutical health sector [2] - The ETF aims to reflect the overall performance of listed companies related to innovative biopharmaceuticals [2]

Group 1: Market Overview - The Hong Kong stock market indices collectively rose, with the Hang Seng Index increasing by 0.58% to 27,183.15 points, the Hang Seng China Enterprises Index up by 0.81% to 9,242.75 points, and the Hang Seng Tech Index rising by 0.62% to 5,451.03 points [2] - Major technology stocks mostly saw gains, with JD.com, Xiaomi, and Alibaba each rising over 1% [3] Group 2: AI Application Stocks - AI application stocks experienced a significant surge, with Zhiyun rising over 21% at one point and closing up over 14%. Other notable gains included Reading Group up over 15% and Fubo Group up over 13% [5] - The attention on AI stocks was driven by the launch of a mysterious model named Pony Alpha on the OpenRouter platform, which quickly became popular among global developers due to its strong coding capabilities and deep optimization for intelligent workflows [5] Group 3: Biotechnology Sector - The biotechnology sector also performed well, with notable increases in stocks such as Fuhong Hanlin up over 7%, and WuXi Biologics and Rongchang Biologics each rising over 4% [6] - Guojin Securities anticipates a performance disclosure window for innovative drug companies in February and March, with expectations for many to reduce losses or turn profitable by 2026, supported by upcoming academic conferences [6]

Market Overview - A-shares experienced narrow fluctuations, with the Sci-Tech Innovation Board showing strong performance, particularly in AI applications and computing chips [1] - The Hong Kong stock market saw a significant rebound in the pharmaceutical sector, with the Hong Kong Innovation Drug ETF (520880) reaching a peak increase of 3.86% and closing up 2.9% [3][5] ETF Performance - The Hong Kong Innovation Drug ETF (520880) recorded a trading volume of 5.9 billion, while the Hong Kong Medical ETF (159137) rose by 2.1%, marking its sixth consecutive day of gains [2][3] - The Sci-Tech Artificial Intelligence ETF (589520) increased by 1.81%, with a peak rise of over 2.4% during the trading session [8] Industry Insights - The Chinese innovative drug sector is experiencing a dual breakthrough in internationalization and commercialization, with over 70% of innovative drug companies reporting positive revenue growth [6][7] - Significant collaborations in the innovative drug space include a strategic partnership between Innovent Biologics and Eli Lilly, valued at up to $8.85 billion, and a $18.5 billion collaboration between CSPC Pharmaceutical and AstraZeneca [6] AI and Technology Developments - ByteDance's recent launches, including the Seedance 2.0 video generation model and Seedream 5.0 image generation model, have generated significant interest in the AI sector [11] - The Sci-Tech Artificial Intelligence ETF (589520) has a substantial exposure to ByteDance, with a weight of 29.42% in its index [11][13] Semiconductor and Chip Industry - The semiconductor equipment industry is experiencing an upward trend, with projected sales growth of 26% in 2026, reaching $791.7 billion [17] - The Sci-Tech Chip ETF (589190) is positioned to benefit from the ongoing "super cycle" in the semiconductor industry, with a focus on domestic production and expansion [15][17] Investment Strategy - Analysts suggest that the current market conditions present a favorable opportunity for investment in innovative drugs and AI sectors, with a recommendation to focus on ETFs that track these industries [7][19] - The Sci-Tech Chip ETF has shown a strong annualized return of 17.93%, outperforming other semiconductor indices [19][20]

Market Overview - The Hong Kong stock market saw all three major indices close higher, with the Hang Seng Index rising by 0.58% to 27,183.15 points, the Hang Seng China Enterprises Index increasing by 0.81% to 9,242.75 points, and the Hang Seng Tech Index up by 0.62% to 5,451.03 points [2] AI Application Stocks - AI application stocks experienced a significant surge, with Zhiyuan (智谱) rising over 21% at one point and closing up by more than 14%. Other notable gains included Reading Group (阅文集团) up over 15% and Fubo Group (阜博集团) up over 13% [6][4] - The excitement in the AI sector was driven by the launch of a new model named Pony Alpha on the OpenRouter platform, which quickly gained popularity among global developers due to its strong coding capabilities and optimized performance for intelligent agent workflows [6] Biotechnology Sector - The biotechnology sector also performed well, with notable stocks such as Fuhong Hanlin (复宏汉霖) increasing by over 7%, and WuXi Biologics (药明生物) and WuXi AppTec (药明康德) both rising by over 4% [9][10] - Analysts from Guojin Securities anticipate a positive earnings disclosure window for innovative drug companies in February and March, with expectations of reduced losses or profitability for several firms by 2026. Upcoming academic conferences are expected to further validate clinical data for domestic innovative drugs [9]

2月10日，A股主要指数窄幅震荡整理，科创综指相对较强；港股早盘一度走高，随后涨幅有所收窄。 具体来看，沪指盘中在4100点上方窄幅震荡，科创综指相对较强，盘中一度涨超1%。截至收盘，沪指涨0.13%报4128.37点，深证成指微涨0.02%，创业板 指跌0.37%，科创综指涨0.31%，沪深北三市合计成交约2.12万亿元，较此前一日减少逾1400亿元。 A股市场超3100股飘绿，酿酒、食品饮料、零售等消费板块集体下挫，电力、有色等板块均走低；传媒板块全线爆发，短剧游戏、影视股表现亮眼，荣信 文化、中文在线、捷成股份等连续两日20%涨停，光线传媒（300251）亦大单封涨停；创新药概念拉升，广生堂涨超10%，万邦德涨停。值得注意的是， 长飞光纤今日再度涨停，股价突破200元大关，续创历史新高。 传媒板块盘中全线爆发，短剧游戏、影视股等表现亮眼。截至收盘，捷成股份、荣信文化、中文在线等连续两日20%涨停，读客文化、幸福蓝海、光线传 媒亦20%涨停，华策影视涨近18%，此外，还有欢瑞世纪、读者传媒、中国电影等约20股10%涨停。 | 代码 名称 | 涨幅% | 现价 | 不正失 | 兴价 | 卖价 | 总量 | ...

Market Overview - The Hong Kong stock market experienced a rise followed by a slight retreat, with the Hang Seng Index closing at 27,183.15 points, up 0.58% or 155.99 points, and a total trading volume of 234.04 billion HKD [1] - The Hang Seng China Enterprises Index increased by 0.81% to 9,242.75 points, while the Hang Seng Tech Index rose by 0.62% to 5,451.03 points [1] Blue-Chip Stocks Performance - Pop Mart (09992) continued its upward trend, closing up 4.9% at 269.8 HKD, contributing 14.96 points to the Hang Seng Index [2] - Other notable blue-chip stocks included CSPC Pharmaceutical Group (01093) up 5.52% at 10.32 HKD, and Innovent Biologics (01801) up 4.98% at 89.65 HKD [2] - New Oriental Education (09901) fell by 4.39% to 46.66 HKD, negatively impacting the index by 2.61 points [2] Sector Highlights - The biotechnology sector showed strong performance, with CSPC Pharmaceutical Group (01093) up 5.52%, and Innovent Biologics (01801) up 4.98% [3] - AI-related stocks surged, with WeMedia Group (00772) rising 15.41% and Zhizhu (02513) increasing by 14.81% [4] - The energy sector saw significant movements, with Dongfang Electric (01072) up 7.11% and Harbin Electric (01133) up 4.51% due to ongoing electricity shortages in North America [6] Investment Opportunities - The global strategic cooperation between Innovent Biologics and Eli Lilly could lead to a potential transaction value of up to 8.85 billion USD, indicating a strong start for business development in 2026 [4] - The AI computing power center project by Ruifeng New Energy (00527) in Zhangjiakou, with a total investment of approximately 24 billion RMB, is expected to enhance the region's technological capabilities [8] Notable Stock Movements - Lexin Outdoor (02720) saw its stock price double on its first trading day, closing up 102.29% at 24.78 HKD [7] - Jiuzhou Intelligent Investment Holdings (09636) issued a profit warning, projecting revenue of approximately 3.43 billion RMB for 2025, an increase of about 1.12 billion RMB from the previous year [10] - Changfei Optical Fiber (06869) reached a new high, closing up 8.88% at 114 HKD, driven by rising fiber prices due to supply-demand imbalances [11]